Temperature concerns could slow the rollout of new coronavirus vaccines
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
During the 2014-2016 Ebola virus outbreak in West Africa, vaccines requiring −80 °C storage were supplied in the Democratic Republic of the Congo using portable and reusable Arktek freezers, allowing the vaccine to be administered to 400,000 people.
“During the 2014–2016 Ebola virus outbreak in West Africa, vaccines requiring −80 °C storage were supplied in the Democratic Republic of the Congo using portable and reusable Arktek freezers, allowing the vaccine to be administered to 400,000 people242.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [242]
Cited by
Sorted by citations
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555 · see citing works
An Update on Self-Amplifying mRNA Vaccine Development
Blakney, A. K., Ip, S., & Geall, A. J. (2021) · Vaccines · doi:10.3390/vaccines9020097 · Cited by 288 · see citing works
Nanocarrier vaccines for SARS-CoV-2
Machhi, J., Shahjin, F., Das, S., Patel, M., Abdelmoaty, M. M., Cohen, J. D., Singh, P., Baldi, A., Bajwa, N., Kumar, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.002 · Cited by 80 · see citing works
“Cold shipment chain for the vaccine, consumes almost 80% of the total vaccine development cost which limit vaccine access in the countries with low and emerging economies [303].”
SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
Chakraborty, S., Mallajosyula, V. V. A., Tato, C. M., Tan, G. S., & Wang, T. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.014 · Cited by 87 · see citing works
Cyclodextrins in Antiviral Therapeutics and Vaccines
Braga, S. S., Barbosa, J. S., Santos, N. E., El-Saleh, F., & Paz, F. A. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030409 · Cited by 55 · see citing works
“These vaccines require, however, refrigeration at very low temperatures (one at−20 and the other at −70 ◦C), which may limit their widespread use [100].”
BackgroundLi, L., Honda-Okubo, Y., Baldwin, J., Bowen, R., Bielefeldt-Ohmann, H., & Petrovsky, N. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.041 · Cited by 38 · see citing works
“However, these COVID-19 vaccines are not without technical limitations with new technologies, such as mRNA-based platforms, being highly temperature sensitive [3] with strict cold storage requirements [4].”
Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model
Kurup, D., Malherbe, D. C., Wirblich, C., Lambert, R., Ronk, A. J., Diba, L. Z., Bukreyev, A. A., & Schnell, M. J. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009383 · Cited by 29 · see citing works
“FDA-approved coronavirus vaccines from Moderna and Pfizer-BioNTech, can be produced efficiently, but they can be costly to produce and have temperature sensitivity (3); furthermore, questions remain unanswered about the longevity of the immune response with mRNA vaccines and if they block transmission.”
BackgroundThe Race for COVID-19 Vaccines: Accelerating Innovation, Fair Allocation and Distribution
Daems, R. P., & Maes, E. (2022) · Vaccines · doi:10.3390/vaccines10091450 · Cited by 24 · see citing works
Accidental Interruption of the Cold Chain for the Preservation of the Moderna COVID-19 Vaccine
Grau, S., Ferrández, O., Martín‐García, E., et al. (2021) · Vaccines · doi:10.3390/vaccines9050512 · Cited by 12 · see citing works
“Although mRNA COVID-19 Moderna unpunctured vials could be stable in standard refrigerators between 2◦ and 8 ◦C (36◦ to 46 ◦F) for 30 days [3] or 8◦ to 25 ◦C (46◦ to 77 ◦F) for a total of 24 h and between 2◦ to 25 ◦C (36◦ to 77 ◦F) after the first dose has been withdrawn for a total of 12 h [4], no information is avail…”
BackgroundHonda-Okubo, Y., Li, L., Andre, G., Leong, K. H., Howerth, E., Bebin-Blackwell, A.-G., Ross, T., & Petrovsky, N. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.063 · Cited by 12 · see citing works
“New vaccine technologies, such as mRNA-based platforms are temperature sensitive with strict cold chain requirements [3,4] presenting challenges for use in”
Hosangadi, D., Martin, E. K., Watson, M., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.065 · Cited by 10 · see citing works
“In the US, pharmacies and clinics initially had to refill mRNA COVID-19 vaccine storage containers with dry ice regularly, and use all vaccines in a shipment within 2 weeks [6].”
Furuhashi, H., Takayasu, L., Isshi, K., et al. (2022) · European Journal Of Oral Sciences · doi:10.1111/eos.12852 · Cited by 10 · see citing works
Mohideen, R. (2021) · IEEE Conference on Norbert Wiener in the 21st Century (21CW) · doi:10.1109/21cw48944.2021.9532527 · Cited by 7 · see citing works
Roozen, G. V. T., Prins, M. L. M., van Binnendijk, R. S., den Hartog, G., Kuiper, V. P., Prins, C., Janse, J. J., Kruithof, A. C., Feltkamp, M. C. W., Kuijer, M., et al. (2021) · medRxiv · doi:10.1101/2021.07.27.21261116 · Cited by 18 · see citing works
“However, mRNA-1273 vaccine can be maintained for 30 days at 2-8 °C, which increases feasibility of use.(15,16) The efficacy of two IM doses of 100 μg mRNA-1273 vaccine was recently demonstrated to be 94% for the prevention of COVID-19 illness as compared with placebo.”
Avoiding exploitation in multinational covid-19 vaccine trials
Iyer, A. A., Millum, J., Grady, C., et al. (2021) · BMJ · doi:10.1136/bmj.n541 · Cited by 6 · see citing works
Thermoelectric insulation for cold temperature vaccine storage
Ordóñez, J. C., & Ordóñez, C. (2021) · IEEE Conference on Technologies for Sustainability · doi:10.1109/sustech51236.2021.9467454 · Cited by 4 · see citing works
Basu, S., & Mishra, S. (2020) · Vaccine Research · doi:10.52547/vacres.7.2.56 · Cited by 1 · see citing works
Recapping The Latest Vaccine Developments
Krishnamoorthy, A. (2021) · Journal of Undergraduate Life Sciences · doi:10.33137/juls.v15i1.35982
Rao, K., & Appavu, R. (2022) · Journal of Student Research · doi:10.47611/jsrhs.v11i2.2567
THE SCIENCE OF HOPE: A COMPREHENSIVE REVIEW OF COVID-19 VACCINE PROGRESS
Srivastava, A., Chaturvedi, V., Wal, P., Srivastava, P., Wal, A., & Yadav, A. (2022) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.53555/jptcp.v29i04.4383
Nanotherapeutics in COVID-19 and associated pulmonary infections
Mir, Z. M., Thakur, P., Arora, R., Kanwar, N., & Baldi, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-28836-4.00016-0 · Cited by 1 · see citing works
- Authors
- Kaiser, J.
- Corresponding author
- Kaiser, Jocelyn
- Venue
- Science
- Published
- 2020-11-16
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3105295709
- Cited by
- 21
- References
- 0
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 5 · 2021: 13 · 2020: 1
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Legal, Health, Environmental and COVID-19 Challenges
- Keywords
- COVID-19 vaccines, vaccine storage temperature, vaccine distribution, vaccine rollout, cold chain, vaccine stability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
